CN103003249B - 嘧啶酮化合物的制备方法 - Google Patents

嘧啶酮化合物的制备方法 Download PDF

Info

Publication number
CN103003249B
CN103003249B CN201180035126.7A CN201180035126A CN103003249B CN 103003249 B CN103003249 B CN 103003249B CN 201180035126 A CN201180035126 A CN 201180035126A CN 103003249 B CN103003249 B CN 103003249B
Authority
CN
China
Prior art keywords
formula
compound
alkyl
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180035126.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103003249A (zh
Inventor
K.S.卡德维尔
C.F.克劳福德
S.H.戴维斯
C.E.韦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103003249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to CN201610182606.0A priority Critical patent/CN105837520A/zh
Publication of CN103003249A publication Critical patent/CN103003249A/zh
Application granted granted Critical
Publication of CN103003249B publication Critical patent/CN103003249B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201180035126.7A 2010-05-17 2011-05-17 嘧啶酮化合物的制备方法 Expired - Fee Related CN103003249B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610182606.0A CN105837520A (zh) 2010-05-17 2011-05-17 嘧啶酮化合物的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34522410P 2010-05-17 2010-05-17
US61/345,224 2010-05-17
PCT/US2011/036821 WO2011146494A1 (en) 2010-05-17 2011-05-17 Novel processes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610182606.0A Division CN105837520A (zh) 2010-05-17 2011-05-17 嘧啶酮化合物的制备方法

Publications (2)

Publication Number Publication Date
CN103003249A CN103003249A (zh) 2013-03-27
CN103003249B true CN103003249B (zh) 2016-04-27

Family

ID=44992024

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180035126.7A Expired - Fee Related CN103003249B (zh) 2010-05-17 2011-05-17 嘧啶酮化合物的制备方法
CN201610182606.0A Pending CN105837520A (zh) 2010-05-17 2011-05-17 嘧啶酮化合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610182606.0A Pending CN105837520A (zh) 2010-05-17 2011-05-17 嘧啶酮化合物的制备方法

Country Status (25)

Country Link
US (2) US9447052B2 (enExample)
EP (1) EP2571857B1 (enExample)
JP (1) JP6027529B2 (enExample)
KR (1) KR20130089157A (enExample)
CN (2) CN103003249B (enExample)
AR (1) AR081399A1 (enExample)
AU (1) AU2011256270B2 (enExample)
BR (1) BR112012030532A2 (enExample)
CA (1) CA2799520C (enExample)
CL (1) CL2012003206A1 (enExample)
CO (1) CO6630197A2 (enExample)
CR (1) CR20120630A (enExample)
DO (1) DOP2012000289A (enExample)
EA (1) EA026569B1 (enExample)
IL (1) IL223068A0 (enExample)
MA (1) MA34301B1 (enExample)
MX (1) MX2012013387A (enExample)
NZ (1) NZ603672A (enExample)
PE (1) PE20130318A1 (enExample)
PH (1) PH12012502247A1 (enExample)
SG (1) SG185559A1 (enExample)
TW (1) TW201209043A (enExample)
UY (1) UY33388A (enExample)
WO (1) WO2011146494A1 (enExample)
ZA (1) ZA201208631B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33388A (es) * 2010-05-17 2011-12-01 Glaxo Group Ltd Nuevos procesos para la preparacion de compuestos de pirimidinona
WO2015087239A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Processes for the preparation of darapladib and its intermediates
WO2015092687A2 (en) 2013-12-17 2015-06-25 Ranbaxy Laboratories Limited Process for the purification of darapladib
US11583596B2 (en) 2017-09-26 2023-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Radiolabeled Darapladib and analogs thereof and their use as imaging compounds
US10866963B2 (en) * 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235776A (en) * 1979-03-15 1980-11-25 Eli Lilly And Company Tetrahydro-2H-benzo[c]pyrroles
US4315939A (en) * 1979-10-13 1982-02-16 Basf Aktiengesellschaft Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, pharmaceutical formulations containing these compounds and use in treating cardiac arrhythmias
US4619941A (en) * 1984-11-19 1986-10-28 American Cyanamid Company N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents
CN1418199A (zh) * 2000-02-16 2003-05-14 史密斯克莱·比奇曼公司 作为ldl－pla2抑制剂的嘧啶－4－酮衍生物
EP1456183B1 (en) * 2001-08-14 2006-04-19 SmithKline Beecham plc Process for preparing 1-(carboxymethyl)-and 1-(aminocarbonyl)-pyrimidin-4-one derivates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1143516B (de) 1961-04-27 1963-02-14 Bayer Ag Verfahren zur Herstellung von Peptiden
US4277465A (en) 1978-08-26 1981-07-07 Kyoto Yakuhin Kogyo Kabushiki Kaisha Adjuvant for promoting absorption of therapeutically active substances through the digestive tract
JP2001522844A (ja) * 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6503745B1 (en) 1998-11-05 2003-01-07 Biocryst Pharmaceuticals, Inc. Cyclopentane and cyclopentene compounds and use for detecting influenza virus
PT1175408E (pt) 1999-05-01 2005-04-29 Smithkline Beecham Plc Derivados sulfonamida
UY33388A (es) * 2010-05-17 2011-12-01 Glaxo Group Ltd Nuevos procesos para la preparacion de compuestos de pirimidinona

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235776A (en) * 1979-03-15 1980-11-25 Eli Lilly And Company Tetrahydro-2H-benzo[c]pyrroles
US4315939A (en) * 1979-10-13 1982-02-16 Basf Aktiengesellschaft Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, pharmaceutical formulations containing these compounds and use in treating cardiac arrhythmias
US4619941A (en) * 1984-11-19 1986-10-28 American Cyanamid Company N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents
CN1418199A (zh) * 2000-02-16 2003-05-14 史密斯克莱·比奇曼公司 作为ldl－pla2抑制剂的嘧啶－4－酮衍生物
EP1456183B1 (en) * 2001-08-14 2006-04-19 SmithKline Beecham plc Process for preparing 1-(carboxymethyl)-and 1-(aminocarbonyl)-pyrimidin-4-one derivates

Also Published As

Publication number Publication date
KR20130089157A (ko) 2013-08-09
SG185559A1 (en) 2012-12-28
EP2571857B1 (en) 2017-08-23
EP2571857A4 (en) 2013-11-20
UY33388A (es) 2011-12-01
AU2011256270B2 (en) 2015-11-26
CO6630197A2 (es) 2013-03-01
MX2012013387A (es) 2012-12-10
JP6027529B2 (ja) 2016-11-16
IL223068A0 (en) 2013-02-03
AU2011256270A1 (en) 2012-12-20
CL2012003206A1 (es) 2013-01-25
TW201209043A (en) 2012-03-01
US9725420B2 (en) 2017-08-08
EA026569B1 (ru) 2017-04-28
WO2011146494A1 (en) 2011-11-24
NZ603672A (en) 2015-01-30
CR20120630A (es) 2013-02-15
CA2799520C (en) 2016-09-13
US20130060028A1 (en) 2013-03-07
CN105837520A (zh) 2016-08-10
CN103003249A (zh) 2013-03-27
MA34301B1 (fr) 2013-06-01
EP2571857A1 (en) 2013-03-27
CA2799520A1 (en) 2011-11-24
BR112012030532A2 (pt) 2015-09-29
US20160347720A1 (en) 2016-12-01
EA201291235A1 (ru) 2013-04-30
JP2013530948A (ja) 2013-08-01
US9447052B2 (en) 2016-09-20
DOP2012000289A (es) 2013-04-15
PE20130318A1 (es) 2013-04-11
PH12012502247A1 (en) 2013-02-04
AR081399A1 (es) 2012-08-29
ZA201208631B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
RU2430092C2 (ru) Способ получения телмисартана
CN103003249B (zh) 嘧啶酮化合物的制备方法
CN105473544B (zh) 3‑(5‑取代的氧‑2,4‑二硝基‑苯基)‑2‑氧‑丙酸酯的化合物，方法及其应用
JP2846042B2 (ja) インドールカルボン酸誘導体の製造法
EP0973769B1 (en) Process for preparing eprosartan
CN101102999A (zh) 制备取代的吲哚的方法
CN101563346A (zh) 制备阿巴卡韦的方法
US6258956B1 (en) Synthesis of 3-amino-3-aryl propanoates
KR101372788B1 (ko) 고순도의 페메트렉시드 이나트륨 염의 제조방법
JPH11292873A (ja) キノロンカルボン酸誘導体の製造方法およびその中間体
US20070037854A1 (en) Process for preparing sulfonamide-containing indole compounds
HK1026206B (en) Process for preparing eprosartan
JP2017186307A (ja) イミダフェナシンの新規中間体、その製造方法及びそれを用いたイミダフェナシンの製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160427

Termination date: 20180517

CF01 Termination of patent right due to non-payment of annual fee